Presentation is loading. Please wait.

Presentation is loading. Please wait.

FORO DE I+D BIOMEDICA GLOBAL LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: CHINA, SINGAPUR Y COREA DEL SUR STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESE.

Similar presentations


Presentation on theme: "FORO DE I+D BIOMEDICA GLOBAL LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: CHINA, SINGAPUR Y COREA DEL SUR STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESE."— Presentation transcript:

1 FORO DE I+D BIOMEDICA GLOBAL LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: CHINA, SINGAPUR Y COREA DEL SUR STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESE BIOSCIENCES AND BIOTECH GROWTH Carlos Martinez-A

2 Medicines are medicines Corn is corn Soya is soya BioPlastic is plastic BioDiesel is diesel. Communicating biotech....

3 European Biotech Industry ? Pre-seedSeedVCIPO Follow on Debt Here? Or along the capital pipeline?

4 European Biotech Industry Fragmentation lack of critical mass: –Product markets –Financial markets –Regulatory frameworks –Centers of excellence and clusters Business attitude Political attitude 10-year gap Lack of all forms of finance

5 European Biotech Industry In 2004 EuropeRatioUS Number of companies2,1501:11,991 Number of employees96,5001:2190,500 R&D expenditure7.6 billion1:321 billion Revenue21.5 billion1:241.5 billion Number of products in clinical development (in 2003) 450 compounds1:21,110 compounds Source: Critical I and EuropaBio

6 European Biotech Industry In 2004 EuropeRatioUS Venture Capital1.1 billion1:2.52.5 billion Equity funding (IPO/2 nd )2.1 billion1:4.59.6 billion Average VC funding per company (overall high-tech) 1.2 million1:56 million Number of listed companies1061:3344 Market Caps (i.e. equity value of listed companies) 19 billion1:9175 billion Source: Critical I and EuropaBio

7 European Biotech Industry … less products in development Lower R&D budgets in Europe, means…

8 Fuente: Ernst & Young, Beyond Borders (Biotech Report), Nov 2005 La productividad de las biotech es superior a la de las farmacéuticas European Biotech Productivity

9 Durante el 2005 las compañías de biotecnología han experimentado una rentabilidad superior a las Farmacéuticas y a los principales índices Fuente: Bloomberg, Abn Amro European Biotech Productivity

10 European Biotech Industry … En su conjunto el valor de capitalización bursátil del sector es igual al valor bursátil de Pfizer y GSK …. con 8 veces el potencial de crecimiento Fuente: GS Global research 2003, SG Cowen Pipeline Plus March 2004, BB Biotech Pfizer y Glaxosmithkline World Biotech Sector Valor de capitalización bursátil (miles de millones de dólares) 334,9 343,3 Pfizer y Glaxosmithkline World Biotech Sector 958 Programas en fase clínica (Numero de programas) 110 Fase I Fase II/III Fase I Fase II/III European Biotech Productivity

11 European Biotech Industry VALUE RISK R&D risks IP risks Financing risks Regulatory risks Market risks Political risks TIME

12 European Biotech Industry VALUE RISK R&D risks IP risks Financing risks Regulatory risks Market risks Political risks Political support TIME

13 The Spanish Government has presented the INGENIO 2010 program to stimulate R&D+i Reach 2% of the GDP for R&D in 2010 and 1.5 % in 2007 Reach 55% private contribution in R&D investment in 2010 Achieve the EU mean in the percentage of the GDP assigned for TIC, to go from 4.8 % in 2004 to 7% in 2010 OBJECTIVES INSTRUMENTS CENIT : public-private collaboration CENIT projects Fund of Capital Risk funds Torres Quevedo Program Increased the number of spin-offs by four folds CONSOLIDER: increase critical mass and researcher excellence Avanz@: convergence of the EU with the Information Society Ingenio 2010 Budget 8.000 M

14 1907: Council for the Extension of Studies and Scientific Research CSIC: over 60 years devoted to R&D Santiago Ramón y Cajal The Nobel Prize in Physiology or Medicine 1906 Severo Ochoa The Nobel Prize in Physiology or Medicine 1959

15 CSIC: over 60 years devoted to R&D Performing Performing: – Multidisciplinary Scientific and Technological Research – Scientific and Technical Assessments – Training of scientific and technical personnel – Management of infrastructures 1 1 CATALUÑA BALEARES ARAGON NAVARRA ASTURIAS CASTILLA-LEON CASTILLA-LA MANCHA MADRID GALICIA EXTREMADURA ANDALUCIA MURCIA C. VALENCIANA 13+[4]+(3) 3+[3] [1] [2] [1] 3+[7] 33+[7]+(5) 1 13+[7]+(1) 2+[3] 1+[1] 2 3+[1] ROMA 1 CANTABRIA PAIS VASCO Organised: Organised: – Network of 116 Institutes (including 40 joint Centres with other Institutions) – 134 Associated Units Collaborating with: – Universities – Other public R&D Organisations – Industries – Enterprises, Professional Associations and Foundations – Regional Governments

16 Budget & Human Resources MEC External resources TOTAL BUDGET: 530 M 38,5 % 61,5 % BUDGET 2.400 Research Staff 4.000 Postgraduate students and Postdocs 4.000 Administrative and Technicians HUMAN RESOURCES TOTAL : 10.400 TOTAL: 204 M REGIONAL GOVERNMENTS NATIONAL RESEARCH PLAN OF R&D EU INDUSTR Y OTHERS 7,9% 40,7% 16,% 18,% 15,%

17 Andalusian Center of Developmental Biology. CABD, Sevilla Andalusian Center of Molecular Biology and Regenerative Medicine. CABIMER, Sevilla Center of Cardiovascular Research. CIC, Barcelona Center for Regenerative Medicine, CMR, Barcelona Center of Biological Research. CIB, Madrid National Center of Biotechnology. CNB, Madrid Institute of Molecular and Cellular Biology Primo Yúfera. IBMCP, Valencia Institute of Molecular and Cellular Biology of Cancer. IBMCC, Salamanca Institute of Molecular Biology of Barcelona. IBMB, Barcelona Laboratory of Plant Genetics-IBMB. Barcelona Center of Molecular Biology, CBM, Madrid Institute of Biology and Molecular Genetics. IBGM, Valladolid Institute of Biomedicine of Valencia. IBV, Valencia Institute of Plant Biology and Photosynthesis. IBVF, Sevilla Institute of Biomedical Research Alberto Sols. IIB, Madrid Institute of Biomedical Research of Barcelona. IIBB, Barcelona Institute of Biochemical Microbiology. IMB, Salamanca Institute of Neurobiology Ramón y Cajal. INRC, Salamanca Institute of Neurosciences of Alicante. INA, Alicante Institute of Parasitology and Biomedicine López Neyra. IPBLN, Granada Unit of Biophysics. UBF, Bilbao CSIC Institutes in the Scientific Area of Biology and Biomedicine 21 Research Centers

18 RECURSOS ECONÓMICOS

19 KNOWLEDGE TRANSFER EMPRESAS DE BASE TECNOLÓGICA

20 CSICs Subscribed Agreements CSIC – Asia Collaboration CHINA Chinese Academy of Sciences (CAS) National Natural Science Foundation (NSFC) Republic of KOREA Korea Science and Engineering Foundation (KOSEF) JAPAN Japan Society for the Promotion of Science (JSPS) TAIWAN National Science Council (NSC) VIETNAM Vietnamese Academy of Science and Technology (VAST) Joint projects and exchange of researchers Bottom-up approach

21 Thank you! Gracias!


Download ppt "FORO DE I+D BIOMEDICA GLOBAL LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: CHINA, SINGAPUR Y COREA DEL SUR STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESE."

Similar presentations


Ads by Google